EQS-Adhoc: IGEA Pharma N.V.: IGEA Pharma receives approval from SIX Exchange Regulation to delay the publication of the 2019 annual report

EQS Group-Ad-hoc: IGEA Pharma N.V. / Key word(s): Miscellaneous 
IGEA Pharma receives approval from SIX Exchange Regulation to delay the 
publication of the 2019 annual report 
 
01-May-2020 / 02:00 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 KR 
The issuer is solely responsible for the content of this announcement. 
 
*IGEA Pharma receives approval from SIX Exchange Regulation to delay the 
publication of the 2019 annual report* 
 
Hoofddorp, the Netherlands, 30 April 2020. IGEA Pharma (SIX: IGPH) today 
announced the grant of a temporary exemption from its disclosure obligations 
with respect to the 2019 annual report. 
 
The sudden shutdown in the capital markets, the overall downturn in market 
sentiment and the various government-ordered lockdowns following the global 
spread of COVID-19 required IGEA to suspend its fundraising initiative as 
disclosed by end of 2019 in connection with the acquisition of the med-tech 
business of Meditalia Srl. As a result, IGEA entered into discussion with a 
major shareholder about alternative financing measures in order to secure 
the funds necessary to continue operating its business. The afore-mentioned 
circumstances as well as the situation around the COVID-19 pandemic led to a 
delay in finalizing the 2019 annual report. IGEA expects to disclose its 
2019 annual report within the coming weeks. 
 
In accordance with SIX Exchange Regulation's decision, this press release 
sets out the relevant section of the SIX Exchange Regulation's decision: 
 
"*I. The exemption application of IGEA Pharma N.V. (Issuer) dated 30 April 
2020 requesting an extension of the deadline to publish its 2019 annual 
report and to file such report with SIX Exchange Regulation AG until 31 May 
2020 at the latest is granted with the following reservation (lit. a) and 
under the following conditions (lit. b):* 
 
*a. SIX Exchange Regulation AG reserves the right to suspend trading of the 
registered shares of the Issuer in case its 2019 annual report is not 
published in accordance with the provisions on ad hoc publicity (Art. 53 of 
the Listing Rules [LR] in connection with the Directive on Ad hoc Publicity 
[DAH]) and not filed with SIX Exchange Regulation AG until Tuesday, 2 June 
2020, 07.30 am CET, at the latest.* 
 
*b. on ad hoc publicity (art. 53 LR in connection with the DAH) concerning 
this decision until Monday, 4 May 2020, 7.30 am CET, at the latest. The 
notice must contain:* 
 
*- the unaltered reproduction of the wording of para. I. of this decision, 
placed in a prominent position;* 
 
*- the reasons for the application of the Issuer requesting an extension of 
the deadline to publish its 2019 annual report and to file such report with 
SIX Exchange Regulation AG;* 
 
*- the unaudited key figures such as net revenues, EBITDA, EBIT, 
profit/loss, balance sheet total, equity etc. for the annual results 2019.*" 
 
Although IGEA has in the meantime secured the funds necessary to continue 
operating its business, IGEA intends to resume its fundraising initiative to 
further strengthen the overall financial situation of the group and 
establish solid products market position. Given the gradual easing of the 
COVID-19 lockdown restrictions, the Company expects to restart its 
fundraising activities in the course of May 2020. 
 
The annual general meeting of IGEA will take place on 26 June 2020. 
 
Furthermore, IGEA today announced the following unaudited key figures for 
its 2019 financial year: 
 
- the group did not generate noteworthy revenues for the year ended 31 
December 2019 (same as the previous year) due to the launch activities 
performed in the period (2019: TUSD 1. Previous year: TUSD 6); 
 
- cost of revenues in 2019 were TUSD 440 (2018: TUSD 198). The main increase 
(TUSD 167) is due to the impairment of certain intangible assets the Group 
does no more consider strategic for its business; 
 
- operating expenses in 2019 amounted to TUSD 1,491 (2018: TUSD 1,275). The 
main differences between 2019 and 2018 are due to increased research and 
development activity (TUSD 122 in 2019; none in 2018) and sales and 
marketing activity (2019: TUSD 529; none in 2018) as well as an overall 
reduction of the general and administration expenses (2019: TUSD 841; 2018: 
TUSD 1'280); 
 
- EBITDA as adjusted (before impairment charge) for 2019 is TUSD -1,616 
(2018: TUSD -1,387; 
 
- EBIT for 2019 is TUSD -1,930 (2018: TUSD -1,467); 
 
- finance income and finance costs were not of a material amount in both 
2019 and 2018 (net financial result of TUSD +22 and TUSD +40 in 2019 and 
2018 respectively, mainly due to exchange gains); 
 
- the loss for the year 2019 is TUSD 1'908 (2018: net loss of TUSD 1,428) 
 
- Total assets as of 31 December 2019 are TUSD 1,067 (2018: TUSD 3,487), 
with a Group equity as of 31 December 2019 of TUSD 568 (2018: TUSD 2,574) 
 
*** 
 
*About IGEA* 
IGEA Pharma focuses on health-tech and med-tech products and devices. 
Health-tech products are exclusively preventative. IGEA commercializes an 
Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit 
to measure non-bound copper in the blood and 'Alz1 Tab', a natural dietary 
supplement designed to reduce blood heavy metals content), and expects to 
launch a diabetes type II prevention set in 2020. Non-ceruloplasmin bound 
copper is an expected Alzheimer's and diabetes type II associated biomarker. 
Determining and regulating non-bound copper can contribute to reduce the 
risk of Alzheimer's and diabetes type II. Med-tech products focuses on 
selected solutions and specialities. IGEA operates in air and inanimate 
environmental surface sanitization with aerosol technology-based devices and 
expects to start commercializing polymeric based medical bags and other 
specialty devices for medical use during 2020. 
 
IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered 
in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl 
 
*Contacts* 
Vincenzo Moccia, CEO, [phone], [e-mail] 
Patrick Pozzorini, CFO, [phone], [e-mail] 
 
*Disclaimer* 
This document constitutes neither an offer to buy nor to subscribe 
securities and neither this document nor any part of it should form the 
basis of any investment decision in IGEA. 
 
The information contained in this press release has been carefully prepared. 
However, IGEA bears and assumes no liability of whatever kind for the 
correctness and completeness of the information provided herein. IGEA does 
not assume an obligation of whatever kind to update or correct information 
contained in this press release whether as a result of new information, 
future events or for other reasons. 
 
This publication may contain specific forward-looking statements and 
assessments or intentions concerning IGEA and its business. Such 
forward-looking statements are subject to known and unknown risks, 
uncertainties and other factors which may result in a substantial divergence 
between the actual results, financial situation, development or performance 
of IGEA and those explicitly or implicitly presumed in these statements. 
Against the background of these uncertainties, readers should not rely on 
forward-looking statements. IGEA assumes no responsibility to update 
forward-looking statements or to adapt them to future events or 
developments, except as may be required by law. 
 
Additional features: 
 
Document: https://eqs-cockpit.com/c/fncls.ssp?u=HHHGYLDCQA [1] 
Document title: 20200430-igea-nv_press -release.pdf 
End of ad hoc announcement 
Language:    English 
Company:     IGEA Pharma N.V. 
             Siriusdreef 17 
             2123 WT Hoofddorp 
             Netherlands 
Phone:       [phone] 
E-mail:      [e-mail] 
Internet:    www.igeapharma.nl 
ISIN:        NL0012768675 
Listed:      SIX Swiss Exchange 
EQS News ID: 1034669 
 
End of Announcement EQS Group News Service 
 
1034669 01-May-2020 CET/CEST 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=064c3bdc05c407439fc310526088a5dd&application_id=1034669&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

April 30, 2020 20:00 ET (00:00 GMT)